APPENDIX 1. 有害事象の叙述

Table 92: Narratives of Deaths, Other Serious and Certain Other Clinically Meaningful Adverse Events

プール 2 とプール 3 に含まれる試験、及び R1500-CL-17100 試験について、すべての死亡、その他の SAE 及び治験薬の投与中止に至った AE の叙述を示す。さらにこれらの試験について一部の AESI についての叙述も含める（詳細は以下の表の脚注を参照）。他の臨床試験についての叙述は、Module 5 の各試験の CSR に示す。死亡及び SAE の一覧を Appendix 2 と Appendix 3 に示す。

Patient Identifier		Serious TEAE	TEAE Leading to permanent study treatment discontinuation	TEAE resulting in death	AESI during TEAE period [1]	CV event with positive adjudication [2]
Pool 2						
[redacted]					Y	
		Y			Y	
		Y				
		Y				
		Y				
		Y				Y
			Y			
			Y			
					Y	
		Y				
			Y			
		Y	Y			
		Y	Y		Y	
		Y				Y
		Y				
		Y			Y	
Pool 3						
[redacted]			Y		Y	
		Y				
		Y			Y	
		Y				
		Y				
		Y				Y
		Y				
		Y				Y
		Y			Y	
		Y			Y	
		Y				
		Y			Y	Y

Patient Identifier	Serious TEAE	TEAE Leading to permanent study treatment discontinuation	TEAE resulting in death	AESI during TEAE period [1]	CV event with positive adjudication [2]
[redacted]	Y			Y	
				Y	
				Y	
				Y	
				Y	
	Y				
	Y	Y		Y	
	Y			Y	
				Y	
	Y			Y	
	Y				
	Y			Y	
	Y				Y
	Y				Y
		Y		Y	
	Y			Y	Y
	Y				
				Y	
	Y		Y		Y
				Y	
	Y				
	Y	Y		Y	
	Y				
	Y				Y
	Y				
	Y				
	Y			Y	Y
	Y				

Patient Identifier	Serious TEAE	TEAE Leading to permanent study treatment discontinuation	TEAE resulting in death	AESI during TEAE period [1]	CV event with positive adjudication [2]
[redacted]	Y				
				Y	
				Y	
	Y				
				Y	
				Y	
				Y	
	Y	Y		Y	
				Y	
	Y				Y
	Y			Y	Y
	Y				
				Y	
	Y			Y	
				Y	
	Y				
	Y		Y		Y
	Y				Y
	Y				
				Y	
R1500-CL-17100					
[redacted]	Y				
				X	
				X	

AESI: adverse event of special interest, CV: cardiovascular, TEAE: treatment-emergent adverse event, Y: yes

[1] Not all AESI for evinacumab are included. Narratives for the following AESI were produced for clinical studies R1500-CL-1629 (double-blind and open-label treatment periods), R1500-CL-1643 (double-blind treatment period), and R1500-CL-1719: anaphylactic reactions, allergic reactions that require consultation with another physician for further evaluation or required medical treatment, increase in ALT or AST ≥3 x ULN (if baseline < ULN), or ≥ 2 times the baseline value (if baseline ≥ ULN), pregnancy, symptomatic overdose with investigational medicinal product, new onset diabetes, and pancreatitis. In addition, for R1500-CL-1719, narratives for patients with increase in CPK >10 x ULN and CPK ≤10 x ULN at baseline were produced. For this same study, narratives were also produced for those TEAEs consistent with the selected AESIs that were classified as an AESI by the investigator, by eCRF specific tick box on the AE page in the study database, that did not otherwise meet pre-specified criteria for an AESI. For the open-label treatment period of R1500-CL-1643, narratives for the AESI new onset diabetes were produced.
[2] CV events were not adjudicated for study R1500-CL-17100.

APPENDIX 2. 死亡の一覧

エビナクマブ臨床試験のうち、評価資料となる試験（R1500-CL-1642 試験、R1500-CL-1331 試験、R1500-CL-1643 試験、R1500-CL-1629 試験、R1500-CL-1719 試験、R1500-CL-17100 試験）及び参考資料となる試験（R1500-HV-1214 試験、R1500-CL-1321 試験、R1500-HTG-1522 試験）において、計 2 件の死亡が報告された。いずれの死亡も R1500-CL-1719 試験の白人（非日本人）で、15 mg/kg IV Q4W のレジメンでエビナクマブ投与を受けていた被験者で発現した。これらの死亡については以下の Table 93 に一覧を示す（Module 5.3.5.2 R1500-CL-1719 Post-text Listing 16.2.7.4 も参照）。これらの死亡の詳細は Appendix 1 に記述する。

Table 93: R1500-CL-1719 Deaths

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1719

Listing 16.2.7.4 Deaths
Safety Analysis Set

Patient Group: New Evinacumab

Patient ID	Age/Sex/Race/ Last Trt Day	Date of Death (Study Day)/ Time of Death	System Organ Class/ Preferred Term/ Verbatim Term	Relationship to/ Study Drug/ Alirocumab/ LMT(specify)	Primary Cause of Death	Death Expected?	Autopsy performed?/ If Yes, findings:	Revelent Circustances Leading to the Death	Last Known Clinical Status within 24 hrs prior to Death
[redacted]	5[redacted]/M/WHITE/ 2019-09-23	20[redacted] (235)/17:58	心臓障害/ 心停止/ SUDDEN CARDIAC ARREST	N/N/N	Sudden cardiac death	No	No	UNKNOWN DATA	REPORTED FROM SPOUSE VIA EMAIL THAT SUBJECT WAS DECEASED ON [redacted], NO OTHER INFORMATION OR DOCUMENTS WILL BE FORTH COMING

Abbreviations: Sex: M= male, F= female; Race: Wh-White, Bk-Black or African American, Ai-American Indian or Alaska Native, An-Asian, Nh-Native Hawaiian or Other Pacific Islander, Oth-Other.
MedDRA (Version 22.0) coding dictionary applied.
AE Status: Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Interim3/Analysis_CSR/Programs/TFL/Generated/l_1380_death.sas ([redacted] 03OCT2022 16:18 SAS Linux 9.4)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1719

Listing 16.2.7.4 Deaths
Safety Analysis Set

Patient Group: Continue Evinacumab

Patient ID	Age/Sex/Race/ Last Trt Day	Date of Death (Study Day)/ Time of Death	System Organ Class/ Preferred Term/ Verbatim Term	Relationship to/ Study Drug/ Alirocumab/ LMT(specify)	Primary Cause of Death	Death Expected?	Autopsy performed?/ If Yes, findings:	Revelent Circustances Leading to the Death	Last Known Clinical Status within 24 hrs prior to Death
[redacted]	5[redacted]/F/WHITE/ 2020-03-10	20[redacted] (367)	心臓障害/ 心筋梗塞/ CARDIAC INFARCTION	N/N/N	Acute myocardial infarction	Unknown	No	WAS HOSPITALIZED IN THE NIGHT OF [redacted] 20[redacted] AND DIED [redacted] 20[redacted]...THAT'S ALL WE KNOW	UNKNOW

Abbreviations: Sex: M= male, F= female; Race: Wh-White, Bk-Black or African American, Ai-American Indian or Alaska Native, An-Asian, Nh-Native Hawaiian or Other Pacific Islander, Oth-Other.
MedDRA (Version 22.0) coding dictionary applied.
AE Status: Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1719/Interim3/Analysis_CSR/Programs/TFL/Generated/l_1380_death.sas ([redacted] 03OCT2022 16:18 SAS Linux 9.4)

APPENDIX 3. 重篤な有害事象の一覧

エビナクマブの臨床試験に関する評価資料又は参考資料のうち、R1500-CL-1642 試験（評価資料）（Module 5.3.3.1 R1500-CL-1642 Post-text Listing 16.2.7.2）又は R1500-CL-1321 試験（参考資料）（Module 5.3.3.2 R1500-CL-1321 Post-text Listing 16.2.7.2.1）で、SAE の報告はなかった。評価資料又は参考資料であるその他の臨床試験で報告された SAE の一覧を以下に示す（全試験のデザインは Table 1 及び Table 2 に記載する）。

SAE がみられた、評価資料となる臨床試験：

- R1500-CL-1331 試験（出典：Module 5.3.5.2 R1500-CL-1331 Post-text Listings 16.2.7.2/1 [for Main Study Period]; Table 94; Post-text Listing 16.2.7.2/2 [for OLE Period]; Table 95）
- R1500-CL-1643 試験（出典：Module 5.3.4.2 R1500-CL-1643 DBTP Post-text Listing 16.2.7.2a; Table 96; Module 5.3.4.2 R1500-CL-1643 OLTP Post-text Listing 16.2.7.2b; Table 97）
- R1500-CL-1629 試験（出典：Module 5.3.5.1 R1500-CL-1629 DBTP Post-text Listing 16.2.7.2a; Table 98; Module 5.3.5.1 R1500-CL-1629 OLTP Post-text Listing 16.2.7.2b; Table 99）
  - OLTP において試験治療下で発現した SAE が発現したアジア人被験者 3 例は、本邦の治験実施施設で登録された被験者であった。
- R1500-CL-1719 試験（出典：Module 5.3.5.2 R1500-CL-1719 Post-text Listing 16.2.7.2; Table 100）
  - 試験治療下で発現した SAE が発現したアジア人被験者 3 例は、本邦の治験実施施設で登録された被験者であった。
- R1500-CL-17100 試験（出典：Module 5.3.5.2 R1500-CL-17100 Post-text Listing 16.2.7.2; Table 101）

SAE がみられた、参考資料となる臨床試験：

- R1500-HV-1214 試験（出典：Module 5.3.3.1 R1500-HV-1214 Post-text Listings 16.2.7.2.1 [Subjects in Group A], 16.2.7.2.2 [Subjects in Group B], 16.2.7.2.3 [Subjects in Group C]; Table 102）
  - この単回投与試験では、すべての SAE はグループ C［TG が 1000 mg/dL（11.3 mmol/L）超の被験者コホート］で発現した。グループ C において試験治療下で発現

した SAE が発現したアジア人被験者 1 例は、本邦以外の治験実施施設で登録された被験者であった。

- R1500-HTG-1522（出典：Module 5.3.5.1 R1500-HTG-1522 (DBTP) Listing 16.2.7.2.1 [First-step Analysis CSR]; Table 103; Module 5.3.5.1 R1500-HTG-1522 (SBTP) [Final CSR] Listing 16.2.7.2.2; Table 104）
  - 試験治療下で発現した SAE が発現したアジア人被験者 2 例は、本邦以外の治験実施施設で登録された被験者であった。

Table 94: R1500-CL-1331 Serious Adverse Events (Main Study Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1331

Listing 16.2.7.2/1 Serious Adverse Events - Main Study Period
(Safety Analysis Set)

Patient ID	Age/ Sex/ Race[a]	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ Stop Date (Study Day)[b]	TEAE/ Serious AE	Injection Site Reaction?/ Infusion Site Reaction?	Grade/ Severity	Relationship to Study Drug/ Relationship to Study Procedure	Action Taken with Study Drug	Outcome	Treatment of AE	Serious AE Type
[redacted]	3[redacted]/M/Un	心臓障害/ 冠動脈疾患/ CORONARY ARTERY DISEASE (SEVERE LEFT MAIN AND THREE-VESSEL DISEASE)	20[redacted](64)/ 20[redacted](66)	Y/Y	N/ N	Grade 2/ Moderate	Not Related/Not Related	NOT APPLICABLE	RECOVERED/RESOLVED	BEGAN APHERESIS ON 17 NOV 2016 PER CLINICIAN ORDER	Requires or Prolongs Hospitalization

[a]Race: Wh-White; Bk-Black or African American; Ai-American Indian or Alaska Native; An-Asian; Nh-Native Hawaiian or Other Pacific Islander; Oth-Other; Unk-Not Reported
[b] If Event Date was before start of treatment date, Study Day = Event Date - Treatment Start Date. If Event Date was on or after start of treatment date, Study Day = (Event Date - Treatment Start Date) + 1

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1331/Final/Analysis_CSR/Programs/TFL/Generated/L_7021_SAE.sas ([redacted]14FEB2019 22:27 SAS Linux 9.4)

MedDRA (Version 17.0) coding dictionary applied.

Table 95: R1500-CL-1331 Serious Adverse Events (OLE Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1331

Listing 16.2.7.2/2 Serious Adverse Events - OLE Period
(Safety Analysis Set)

Patient ID	Age/ Sex/ Race[a]	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ Stop Date (Study Day)[b]	TEAE/ Serious AE	Injection Site Reaction?/ Infusion Site Reaction?	Grade/ Severity	Relationship to Study Drug/ Relationship to Study Procedure	Action Taken with Study Drug	Outcome	Treatment of AE	Serious AE Type
[redacted]	3[redacted]/M/Wh	心臓障害/ 冠動脈狭窄/ MULTIPLE CORONARY STENOSIS	20[redacted](64)/ 20[redacted](73)	Y/Y	N/ N	Grade 3/ Severe	Not Related/Not Related	DOSE NOT CHANGED	RECOVERED/RESOLVED	Medication	Requires or Prolongs Hospitalization
[redacted]	1[redacted]/M/Wh	呼吸器、胸郭および縦隔障害/ 気管支痙攣/ BRONCHOSPASM DUE TO ALLERGIC REACTION TO INGESTION OF CHIPS CONTAINING LENTILS AND CHICKPEAS	20[redacted](372)/ 20[redacted](372)	Y/Y	N/ N	Grade 2/ Moderate	Not Related/Not Related	DOSE NOT CHANGED	RECOVERED/RESOLVED	Medication	Other Medically Important Serious Event

[a]Race: Wh-White; Bk-Black or African American; Ai-American Indian or Alaska Native; An-Asian; Nh-Native Hawaiian or Other Pacific Islander; Oth-Other; Unk-Not Reported
[b] If an event occurred before the first study treatment in OLE, Study Day=(Event Date - First Study Treatment Date in OLE). Otherwise, Study Day = (Event Date - First Study Treatment Date in OLE) + 1

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1331/Final/Analysis_CSR/Programs/TFL/Generated/L_7022_SAE_OLE.sas [redacted]14FEB2019 22:28 SAS Linux 9.4)

MedDRA (Version 17.0) coding dictionary applied.

Table 96: R1500-CL-1643 Serious Adverse Events (Double-blind Treatment Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1643

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]M/WHITE/ 169	呼吸器、胸郭および縦隔障害/ 労作性呼吸困難/ SHORTNESS OF BREATH ON EXERTION	20[redacted](116)/ 2/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 5 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]F/WH ITE/ 172	心臓障害/ 冠動脈疾患/ CORONARY ARTERY DISEASE	20[redacted]50)/ Ongoing/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	NOT RECOVERED/ NOT RESOLVED
[redacted]	7[redacted]F/WH ITE/ 170	神経系障害/ 失神/ SYNCOPAL EPISODE	20[redacted]66)/ 3/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
	7[redacted]F/WH ITE/ 170	傷害、中毒および処置合併症/ 腱断裂/ TORN TENDON LEFT HIP	20[redacted]88)/ 5/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 5 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	7[redacted]F/WHITE/ 170	神経系障害/ 高血圧性脳症/ HYPERTENSIVE ENCEPHALOPATHY	20[redacted](111)/ 6/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	4[redacted]F/WHITE/ 176	血管障害/ 末梢動脈閉塞性疾患/ PERIPHERAL ARTERY DISEASE	20[redacted](28)/ 2/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	5[redacted]F/WHITE/ 171	傷害、中毒および処置合併症/ 脛骨骨折/ TIBIA FRACTURE RIGHT LATERALE	20[redacted](125)/ Ongoing/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERING/ RESOLVING
[redacted]	6[redacted]M/WHITE/ 169	心臓障害/ 冠動脈疾患/ ACUTE CORONARY ARTERY DISEASE (UNSTABLE ANGINA)	20[redacted](42)/ 3/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DRUG INTERRUPTED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	5[redacted]F/WHITE/ 29	臨床検査/ アラニンアミノトランスフェラーゼ増加/ ALT INCREASE	20[redacted](141)/ 13/ T	N	Other Medically Important Serious Event	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED
	5[redacted]F/WHITE/ 29	心臓障害/ 心房細動/ PAROXISMAL ATRIAL FIBRILLATION	20[redacted](167)/ 15/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED
[redacted]	5[redacted]M/WHITE/ 140	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 神経膠芽細胞腫/ GLIOBLASTOMA	20[redacted](144)/ Ongoing/ T	N	Other Medically Important Serious Event	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DRUG WITHDRAWN	NOT RECOVERED/ NOT RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	5[redacted]F/OTHER/ 28	免疫系障害/ アナフィラキシー反応/ ANAPHYLAXIS	20[redacted](28)/ 1/ T	Y	Other Medically Important Serious Event	Moderate	Related/ Not Related/ Not Related	Not Related/ Not Related	DRUG WITHDRAWN	RECOVERED/ RESOLVED
[redacted]	5[redacted]M/WHITE/ 173	心臓障害/ 不安定狭心症/ UNSTABLE ANGINA	20[redacted](-107)/ 3/ Pre	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]05DEC2019 15:23 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Table 97: R1500-CL-1643 Serious Adverse Events (Open-label Treatment Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1643

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]/M/WHITE/ 481	良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）/ 移行上皮癌/ PAPILLARY UROTHELIAL CARCINOMA	20[redacted] (512)/ 12/ T	N	Other Medically Important Serious Event	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED
	6[redacted]/M/WHITE/ 481	心臓障害/ 心房細動/ RECURRENT ATRIAL FIBRILLATION	20[redacted] (558)/ 2/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]/F/WHITE/ 477	神経系障害/ 頚動脈狭窄/ WORSENING OF STENOSIS ON THE LEFT CAROTID, USG 26/JUL/2019-STENOSIS 80%	20[redacted](228)/ 25/ T	N	Other Medically Important Serious Event	Mild	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	6[redacted]/F/WHITE/ 476	胃腸障害/ 消化管運動障害/ INTESTINAL DYSKINESIA	20[redacted](267)/ 9/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Final_IV/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted] 11AUG2021 09:56 SAS Linux 9.4)

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Placebo IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	7[redacted]/M/BLACK OR AFRICAN AMERICAN/ 477	感染症および寄生虫症/ コロナウイルス感染/ COVID-19	20[redacted] (394)/ 11/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DRUG INTERRUPTED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Final_IV/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted] 11AUG2021 09:56 SAS Linux 9.4)

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 5 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	5[redacted]/F/WHITE/ 447	肝胆道系障害/ 胆嚢ポリープ/ GALL BLADDER POLYP	20[redacted] (404)/ 2/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	5[redacted]/F/WHITE/ 478	筋骨格系および結合組織障害/ 関節滲出液/ RIGHT KNEE EFFUSION	20[redacted] (380)/ 5/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	5[redacted]/M/WHITE/ 468	呼吸器、胸郭および縦隔障害/ 肺塞栓症/ BILATERAL PULMONARY EMBOLISM (VENOUS)	20[redacted] (250)/ 4/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Final_IV/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted] 11AUG2021 09:56 SAS Linux 9.4)

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]/F/WHITE/ 478	心臓障害/ 動悸/ WORSENING HEART PALPITATIONS	20[redacted] (392)/ 4/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
	6[redacted]/F/WHITE/ 478	呼吸器、胸郭および縦隔障害/ 呼吸困難/ DYSPNEA	20[redacted] (392)/ 8/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
	6[redacted]/F/WHITE/ 478	心臓障害/ 心房細動/ ATRIUM FIBRILATION	20[redacted] (398)/ 1/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
	6[redacted]/F/WHITE/ 478	心臓障害/ 心房細動/ ATRIUM FIBRILATION	20[redacted] (402)/ 1/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Final_IV/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted] 11AUG2021 09:56 SAS Linux 9.4)

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]/F/WHITE/ 477	一般・全身障害および投与部位の状態/ 胸痛/ CHEST PAIN	20[redacted] (432)/ 2/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
MedDRA (Version 22.0) coding dictionary applied.
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1643/Final_IV/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted] 11AUG2021 09:56 SAS Linux 9.4)

Table 98: R1500-CL-1629 Serious Adverse Events (Double-blind Treatment Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1629

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	3[redacted]F/OTHER/ 172	精神障害/ 自殺企図/ SUICIDE ATTEMPT AS DEEP PHLEBOTOMY	20[redacted](145)/ 3/ T	N	Requires or Prolongs Hospitalization|Is Life Threatening	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	5[redacted]M/WHITE/ 169	一般・全身障害および投与部位の状態/ 非心臓性胸痛/ NON CARDIAC ATYPICAL CHEST PAIN	20[redacted](-22)/ 1/ Pre	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]18NOV2019 09:31 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2a Serious Adverse Events
Double-blind Safety Analysis Set - DBTP

Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Study Drug?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	3[redacted]F/BLACK OR AFRICAN AMERICAN/ 169	感染症および寄生虫症/ 尿路性敗血症/ URINARY TRACT INFECTION WITH SEPSIS	20[redacted]112)/ 18/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DRUG INTERRUPTED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim1/Analysis_CSR/Programs/TFL/Generated/l_1320_sae_db.sas ([redacted]18NOV2019 09:31 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Table 99: R1500-CL-1629 Serious Adverse Events (Open-label Treatment Period)

Regeneron Pharmaceuticals, Inc.
Protocol: R1500-CL-1629

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	6[redacted]M/ASIAN/ 330	心臓障害/ 狭心症/ ANGINA PECTORIS	20[redacted]248)/ 3/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	6[redacted]F/ASIAN/ 337	傷害、中毒および処置合併症/ 頚動脈再狭窄/ WORSENING OF CAROTID ARTERY RESTENOSIS	20[redacted]354)/ Ongoing/ T	N	Requires or Prolongs Hospitalization	Moderate	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	
[redacted]	6[redacted]M/ASIAN/ 309	心臓障害/ うっ血性心不全/ CONGESTIVE HEART FAILURE	20[redacted]351)/ Ongoing/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	NOT APPLICABLE	RECOVERING/ RESOLVING

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted]28FEB2020 13:33 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	5[redacted]M/WHITE/ 309	心臓障害/ 不安定狭心症/ UNSTABLE ANGINA	20[redacted]294)/ 5/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	3[redacted]M/WHITE/ 309	心臓障害/ 冠動脈疾患/ WORSENING OF SIGNIFICANT OCCLUSIVE CORONARY ARTERY DISEASE	20[redacted]254)/ 2/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	2[redacted]F/WHITE/ 309	腎および尿路障害/ 腎石灰沈着症/ BILATERAL SYMMETRICAL MEDULLARY NEPHROCALCINOSIS	20[redacted]173)/ 3/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted]28FEB2020 13:33 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	2[redacted]F/WH ITE/ 309	感染症および寄生虫症/ 腎盂腎炎/ RIGHT SIDED PYELONEPHRITIS	20[redacted]188)/ 4/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
[redacted]	5[redacted]F/WH ITE/ 311	傷害、中毒および処置合併症/ 心臓処置合併症/ COMPLICATION OF AORTIC VALVE SURGERY	20[redacted]285)/ 1/ T	N	Is Life Threatening	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED
	5[redacted]F/WH ITE/ 311	血管障害/ 大動脈狭窄/ WORSENING OF AORTIC STENOSIS	20[redacted]285)/ 1/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas [redacted]28FEB2020 13:33 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.

Listing 16.2.7.2b Serious Adverse Events
Open-label Safety Analysis Set - OLTP

DB Treatment Group as Treated: Evinacumab 15 mg/kg IV Q4W

Patient Number	Age/Sex/ Race/ Last Trt Day	System Organ Class/ Preferred Term/ Verbatim Term	Start Date (Study Day)/ AE duration (days)/ AE Status	Infusion Related Reaction	Serious Event Type	Severity	Relationship to Evinacumab?/ Alirocumab?/ LMT(specify)	Relationship to Protocol Required Procedure?/ Study Conduct	Action Taken with Study Drug	Outcome
[redacted]	5[redacted]F/WH ITE/ 311	心臓障害/ 急性心筋梗塞/ STEMI	20[redacted]303)/ 1/ T	N	Requires or Prolongs Hospitalization	Severe	Not Related/ Not Related/ Not Related	Not Related/ Not Related	DOSE NOT CHANGED	RECOVERED/ RESOLVED

Abbreviations: M= male, F= female. AE status:Pre=pre-treatment;T=treatment emergent; Post=post-treatment; AE duration=(end date-onset date+1)
Study Day= Event Date - First Dosing Date, if Event Date was before First Dosing Date/Time, Study Day= Event Date - First Dosing Date + 1, if Event Date was on or after First Dosing Date/Time.

/sasdata/Data/Production/BDM/R1500/R1500-CL/R1500-CL-1629/Interim2/Analysis_CSR/Programs/TFL/Generated/l_1330_sae_ol.sas ([redacted]28FEB2020 13:33 SAS Linux 9.4)

MedDRA (Version 22.0) coding dictionary applied.